GlassScriptPhysician profile
Zu Yu Chen
NPI 1023413747
$11,377.72
in general payments reported to CMS, 2019-2025
20 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $301 · 2021: $901 · 2022: $1,796 · 2023: $2,227 · 2024: $2,834 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,841 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,841.43 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,417.27 | 2019-2025 | Evenity, Otezla, Repatha |
| Gilead Sciences, INC. | $3,194.44 | 2019-2025 | Vemlidy |
| Abbvie INC. | $1,131.57 | 2022-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $735.80 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.55 | 2020-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $401.75 | 2019-2023 | |
| Axsome Therapeutics, INC. | $387.50 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $337.69 | 2023-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $311.31 | 2024 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $161.06 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Pfizer INC. | $105.15 | 2025 | |
| Janssen Pharmaceuticals, INC | $103.37 | 2019 | |
| Phathom Pharmaceuticals, INC. | $76.12 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $66.00 | 2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.08 | 2023 | |
| Astellas Pharma US INC | $26.11 | 2024 | Veozah |
| Agios Pharmaceuticals, INC. | $24.01 | 2024 | |
| Oxford Immunotec USA INC | $18.94 | 2022 | |
| Radius Health, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zu Yu Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.